Literature DB >> 27242124

Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.

Charles E Leonard1, Xu Han2, Warren B Bilker3, James H Flory4, Colleen M Brensinger5, David A Flockhart6, Joshua J Gagne7, Serena Cardillo8, Sean Hennessy9.   

Abstract

We conducted high-dimensional propensity score-adjusted cohort studies to examine whether thiazolidinedione use with a statin or fibrate was associated with an increased risk of severe hypoglycemia. We found that concomitant therapy with a thiazolidinedione+fibrate was associated with a generally delayed increased risk of severe hypoglycemia.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cohort studies; Drug interactions; Hypoglycemia; Medicaid; Pharmacoepidemiology; Thiazolidinediones

Mesh：

Substances：

Year:  2016        PMID： 27242124      PMCID： PMC4890073          DOI： 10.1016/j.diabres.2016.03.006

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  20 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 2.  Do statins beneficially or adversely affect glucose homeostasis?

Authors:  Michael S Kostapanos; George L Liamis; Haralampos J Milionis; Moses S Elisaf
Journal:  Curr Vasc Pharmacol       Date:  2010-09       Impact factor: 2.719

3.  Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.

Authors:  Fanny Lalloyer; Brigitte Vandewalle; Frédéric Percevault; Gérard Torpier; Julie Kerr-Conte; Maaike Oosterveer; Réjane Paumelle; Jean-Charles Fruchart; Folkert Kuipers; François Pattou; Catherine Fiévet; Bart Staels
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

4.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

Authors:  S Schwartz; P Raskin; V Fonseca; J F Graveline
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

Authors:  Tiina Jaakkola; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-07       Impact factor: 4.080

6.  Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle.

Authors:  M Furuhashi; N Ura; H Murakami; M Hyakukoku; K Yamaguchi; K Higashiura; K Shimamoto
Journal:  J Endocrinol       Date:  2002-08       Impact factor: 4.286

Review 7.  Interaction between free fatty acids and glucose metabolism.

Authors:  Guenther Boden
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-09       Impact factor: 4.294

Review 8.  Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.

Authors:  Charles A Reasner
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

9.  Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia.

Authors:  Taner Damci; Serkan Tatliagac; Zeynep Osar; Hasan Ilkova
Journal:  Eur J Intern Med       Date:  2003-10       Impact factor: 4.487

Review 10.  PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Authors:  Barbara Gross; Bart Staels
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-12       Impact factor: 4.690
View more
  2 in total

1.  Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.

Authors:  Charles E Leonard; Xu Han; Colleen M Brensinger; Warren B Bilker; Serena Cardillo; James H Flory; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-11-06       Impact factor: 2.890

2.  Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data.

Authors:  Katsiaryna Bykov; Hu Li; Sangmi Kim; Seanna M Vine; Vincent Lo Re; Joshua J Gagne
Journal:  Clin Pharmacol Ther       Date:  2020-12-17       Impact factor: 6.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.